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Abstract
Background: The number of people with diabetes is growing rapidly. Diabetes can cause nerve damage leading to
severe pain in the feet, legs and hands, which is known as diabetic peripheral neuropathic pain (DPNP). In the UK,
the National Institute for Health and Care Excellence (NICE) recommends amitriptyline, duloxetine, pregabalin or gabapentin
as initial treatment for DPNP. If this is not effective, adding one of the other drugs in combination with the
first is recommended. NICE points out that these recommendations are not based on robust evidence. The
OPTION-DM randomised controlled trial has been designed to address this evidence deficit, with the aims
of determining the most clinically beneficial, cost-effective and tolerated treatment pathway for patients
with DPNP.
Methods/design: A multicentre, double-blind, centre-stratified, multi-period crossover study with equal
allocation to sequences (1:1:1:1:1:1) of treatment pathways. Three hundred and ninety-two participants will
be recruited from secondary care DPNP centres in the UK. There are three treatment pathways: amitriptyline
supplemented with pregabalin, pregabalin supplemented with amitriptyline and duloxetine supplemented
with pregabalin. All participants will receive all three pathways and randomisation will determine the order
in which they are received. The primary outcome is the difference between 7-day average 24-h pain scores
on an 11-point NRS scale measured during the final follow-up week of the treatment pathway. Secondary
outcomes for efficacy, cost-effectiveness, safety, patient-perceived tolerability and subgroup analysis will be
measured at week 6 and week 16 of each pathway.
Discussion: The study includes direct comparisons of the mainstay treatment for DPNP. This novel study is
designed to examine treatment pathways and capture clinically relevant outcomes which will make the results generalisable
to current clinical practice. The study will also provide information on health economic outcomes and will include a
subgroup study to provide information on whether patient phenotypes predict response to treatment.
Trial registration: ISRCTN17545443. Registered on 12 September 2016.
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Background
In August 2015, Diabetes UK announced that the preva-
lence of diabetes had increased by 60% over the previous
decade to 3.3 million. Diabetic peripheral neuropathic
pain (DPNP) is a serious complication affecting up to
20–26% of these patients [1, 2]. With the prevalence of
diabetes set to increase by epidemic proportions over
the next decade, DPNP will pose a major treatment chal-
lenge [3, 4]. With advanced disease the pain can extend
above the feet and may involve the whole of the legs,
and when this is the case there is often upper limb in-
volvement also. Moderate-to-severe unremitting lower
limb pain is present in over 70% of sufferers [2, 5] and
causes insomnia, poor Quality of Life (QoL), unemploy-
ment and depression [6–9].
The mainstay of treatment for DPNP is pharmacothe-
rapy. Recent National Institute for Health and Care Excel-
lence (NICE) guidance (173) [10] recommends a choice of
amitriptyline, duloxetine, pregabalin or gabapentin as initial
treatment. All are licensed treatments for DPNP except
amitriptyline, which has been used off-license for more
than 25 years. There is moderate evidence for the efficacy
of each drug based on Cochrane reviews [11–14] and
meta-analyses [15–17], but the best we can hope for any
monotherapy is 50% pain relief in 50% of patients [10]. This
is often accompanied by side effects (dry mouth, constipa-
tion, sedation, dizziness, falls, nausea, oedema, etc.) in
around 10–20% depending on dose. NICE recommends
combination treatment if initial treatment is not effective
(the majority) [10]. However, as NICE points out recom-
mendations are not based on robust evidence as: (1) there
are few well-designed head-to-head studies comparing the
first-line drugs and their combinations; (2) most studies
were flawed with inadequate power, inappropriate
endpoints, short duration of follow-up and (3) many ran-
domised controlled trials (RCTs) lacked appropriate
health-related QoL (HRQL) measures including functional-
ity and failed to measure impact of drug-related adverse
effects on health economics and QoL [10]. An RCT is
needed to address these deficiencies.
The aims of the OPTION-DM study will be to determine
the most clinically beneficial, cost-effective and tolerated
treatment pathway for patients with DPNP. The study has
been designed to have direct clinical applicability in the
management of DPNP following completion.
Study objectives
1. To evaluate if at least one of the three pathways is
superior to the other pathways in terms of pain
symptoms, quality of life and cost-effectiveness
2. To evaluate if at least one monotherapy is superior
to a different monotherapy in improving pain
symptoms
3. To describe Adverse Event and Serious Adverse Event
data for the different treatment pathways for DPNP
4. To conduct an exploratory analysis to investigate




OPTION-DM is a multicentre, double-blind, centre-
stratified, multi-period crossover study with equal alloca-
tion to sequences (1:1:1:1:1:1) of treatment pathways.
Three hundred and ninety-two participants will be
recruited from secondary care DPNP centres in the UK.
A list of participating centres can be found at the end of
this paper. Recruitment is expected to take place over
12 months beginning in October 2017. Follow-up will
continue for another 12 months.
The study contains an internal pilot with stop-go criteria
to assess its feasibility. The recruitment and retention will be
reviewed in relation to targets agreed with the funder after
6 months of recruitment. If met, an assessment of attrition
to the trial is scheduled after 12 months of recruitment.
The study protocol was written in accordance with the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines (see Additional file 1:
SPIRIT Checklist).
Participants
A number of approaches will be used to identify potential
participants: hospital database searches will be completed
at each of the study centres; potential patients may be iden-
tified during routine hospital appointments at a study
centre; the general practitioner (GP) patient registers at
around 80 GP surgeries aligned to the study centres will be
checked for patients with a diagnosis of diabetes and pre-
scriptions for neuropathic pain medications; Participant
Identification Centres (PIC) will be utilised; community po-
diatry services will be engaged to encourage referrals of po-
tential patients, if applicable; details of the study will be
advertised through the use of posters and leaflets in various
clinics (for example, diabetes outpatient clinics or GP sur-
geries); the study will be advertised in a number of loca-
tions, such as on charity websites, in local libraries, local
newspapers and via local radio stations to inform potential
participants about the study.
Potentially eligible participants will be provided with
the participant information sheet. Informed consent will
be obtained by a medically qualified site investigator
trained in Good Clinical Practice.
Eligibility criteria
Inclusion criteria
1. Participant aged ≥ 18 years
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2. Neuropathic pain affecting both feet and / or hands
for at least 3 months or taking pain medication for
neuropathic pain for at least 3 months
3. Bilateral distal symmetrical neuropathic pain
confirmed by the Douleur Neuropathique 4 (DN4)
questionnaire at the screening visit [18]
4. Bilateral distal symmetrical polyneuropathy
confirmed by a modified Toronto Clinical
Neuropathy Score (mTCNS) > 5 at the screening
visit [19]
5. Stable glycaemic control (HbA1c < 108 mmol/mol)
6. Participants will have a mean total pain intensity of
at least 4 on an 11-point numeric rating scale (NRS;
with 0 being ‘no pain’ and 10 ‘worst pain imagin-
able’) during 1 week off pain medications (baseline
period)
7. Willing and able to comply with all the study
requirements and be available for the duration of
the study. This will be a 1-year study in which all
participants will undergo all treatment pathways re-
gardless of treatment response and this point will
be made clear
8. Willing to discontinue current neuropathic-pain-
relieving medications
9. Informed consent form for study participation
signed by participant
Exclusion criteria
1. Non-diabetic symmetrical polyneuropathies
2. History of alcohol/substance abuse which would, in
the opinion of the investigator, impair their ability
to take part in the study
3. History of severe psychiatric illnesses which would,
in the opinion of the investigator, impair their
ability to take part in the study
4. History of epilepsy
5. Contraindications to study medications
6. Pregnancy/breast feeding or planning pregnancy
during the course of the study
7. Use of prohibited concomitant treatment that could
not be discontinued
8. Use of high-dose morphine equivalent
(> 100 mg/day)
9. Liver disease (AST/ALT > 2 times upper limit of
normal)
10. Significant renal impairment (estimated glomerular
filtration rate (eGFR) < 30 ml/min/1.73m2)
11. Heart failure New York Heart Association
(NYHA) ≥ class II
12. Clinically significant cardiac arrhythmias on 12-lead
ECG or current history of arrhythmia
13. Patients with a recent myocardial infarction
(< 6 months prior to randomisation)
14. Postural hypotension (reduction of > 20 mmHg)
15. Prostatic hypertrophy or urinary retention to an
extent which would, in the opinion of the
investigator, be a contraindication to the study
medication
16. Patients with other painful medical conditions
where the intensity of the pain is significantly more
severe than their diabetic peripheral neuropathic
pain (patients will not be excluded if the pain is
transient in nature)
17. Any suicide risk as judged by the investigator or as
defined by a score of ≥ 2 on the suicide risk
questionnaire
18. Significant language barriers which are likely to
affect the participant's understanding of the
medication schedule or ability to complete outcome
questionnaires
19. Concurrent participation in another clinical trial of
an investigational medicinal product
20. Major amputations of the lower limbs
21. Active diabetic foot ulcers
Washout and baseline period
After providing consent, participants will be instructed
on how to washout neuropathic pain medication. The
dose will be tapered for 3 days with complete washout
for 1–4 days at the investigator's discretion. If the
participant is on combination therapy then all drugs will
be tapered at once. For participants taking 50-100-mg
morphine equivalent the dose will be tapered over a
period of up to 2 weeks.
Following the initial washout period, participants will
enter the baseline period for 1 week. No neuropathic pain
medication is permitted during this week with the excep-
tion of paracetamol. From the daily pain scores collected
during the baseline period, a mean for the week will be
determined and used in subsequent analysis.
Interventions
Treatment pathways
The OPTION-DM will study three treatment pathways:
 Amitriptyline supplemented with pregabalin
(A-P Pathway)
 Duloxetine supplemented with pregabalin
(D-P Pathway)
 Pregabalin supplemented with amitriptyline
(P-A Pathway)
Randomisation
Participants will be centrally randomised in the study by
the study team at site using the Clinical Trials Research
Unit (CTRU) online randomisation system. All partici-
pants will receive all three treatment pathways (Table 1).
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Randomisation will determine the order in which they
receive the treatment pathways. Participants will be
assigned to one of the six sequences based on a prede-
termined randomisation schedule stratified by study site
using permuted blocks.
Treatment phases
Each treatment pathway has two treatment phases
(Fig. 1). During the first treatment phase, participants
will receive monotherapy with the first-line treatment in
the pathway. This will last for a total of 6 weeks, inclu-
ding the dose-titration phase.
At the week-6 follow-up visit a decision will be taken
to either continue on monotherapy or to add second-
line treatment as combination therapy based on the
7-day average 24-h pain NRS score during the week pre-
ceding the study visit. Participants will be divided into
‘responders’ (pain score ≤ 3) and ‘non-responders’ (pain
score > 3) and this will be used to guide treatment
during the second treatment phase.
The second treatment phase will last for a total of
10 weeks. Non-responders will commence combination
therapy with the addition of second-line treatment for
10 weeks, including the dose-titration phase. Responders
will continue on monotherapy for the remainder of
treatment phase 2, but this decision may be reversed up
to week 13 in the event that a participant becomes a
‘non-responder’ later in the second treatment phase.
The dose titration will follow the same schedule.
At the week-16 follow-up visit, participants will be ad-
vised to taper-down study medication (3 days) and stop
the medication completely (4 days) before commencing
the next treatment pathway. The taper dose will be one
dose level below the maximum tolerated dose. Partici-
pants on dose level 1 will not require a taper dose and
will stop study medication completely for 7 days. The
first and second treatment phases will be repeated until
the participant completes all three pathways.
Dose titration
There will be three dose levels for each drug and partici-
pants will always start on the lowest dose level of each
drug. The schedule of dose escalation will be identical in
each treatment pathway, see Fig. 2a and b. Patients with
renal insufficiency will receive a modified dosing schedule:
eGFR will be measured at screening and at week 16 of
each pathway and patients whose eGFR was 30–59 ml/
min at their most recent test will receive a lower dose of
pregabalin. Pharmacy will be informed of the latest eGFR
result with each prescription in order to ensure that the
correct dose of pregabalin is dispensed.
During the first 2 weeks of each treatment phase, the
dose will be escalated towards the maximum tolerated
dose or maximum permitted dose, whichever is first,
based on treatment response (based on the 24-h pain
NRS score) and side effect profile.
During the weekly telephone calls and scheduled study
visits, the research nurse will evaluate response to treat-
ment and adverse effects to guide dose titration accor-
dingly. If patients are receiving adequate pain relief
(24-h pain NRS score ≤ 3) at dose level 1 or 2 then the
dose will not be increased further. Patients will also be
asked to rate any reported side effects. These will be
graded (mild, moderate or severe) and whether side
effects are tolerable or intolerable. Any severe or intole-
rable side effects will require a medication review (i.e.
consider dose reduction or discontinuation).
Switching treatment during a pathway
At the week-6 visit if there was no change in pain scores
from the pre-treatment pathway (baseline), participants
will switch to the second-line treatment in the treatment
pathway.
If there is significant intolerance to first-line treatment;
for example, due to side effects which are severe or
which the patient describes as intolerable, participants
can switch to the second-line treatment in the treatment
pathway as a monotherapy. In this situation the switch
can be made immediately, at any time, without the need
to washout the first-line treatment. The second-line
treatment will be continued as a monotherapy for the
remainder of the treatment pathway; i.e. up to the
week-16 visit. If there is significant intolerance to the
second-line treatment in the pathway, the participant
will stop the study treatment but will remain in the
study for follow-up.
Blinding
OPTION-DM is a double-blind study and blinding of
medication will be maintained with over-encapsulated
drugs and matching placebos. The treating physician will
be aware of the dose level but not the treatment itself.
Due to the complex dosing schedule, the pharmacist at
each study centre will be unblinded and a member of
staff at Sheffield CTRU responsible for site monitoring
will also be unblinded.








Sequence 1 A-P D-P P-A
Sequence 2 A-P P-A D-P
Sequence 3 D-P A-P P-A
Sequence 4 D-P P-A A-P
Sequence 5 P-A A-P D-P
Sequence 6 P-A D-P A-P
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Emergency unblinding can be performed where the
knowledge of the treatment allocation would change the
participant’s clinical management or to facilitate safety
reporting to the regulatory authority and Research Ethics
Committee.
Adherence
Participants will be provided with detailed guidance re-
garding how to take their study medication. This will be
reinforced with written instructions and participants will
be directed to complete a daily medication diary to rec-
ord which doses they have taken.
Participants will be asked to return all bottles of
study medication, including empty bottles and any
unused medication. These will be reviewed and the
remaining capsules counted to monitor adherence to
study treatment. The study nurse will provide further
guidance to participants if there is concern about
adherence levels.
Concomitant medications
Participants will maintain their current schedule of treat-
ment throughout the duration of the study. Changes to
concomitant medications will be documented at each
study visit. Participants may take paracetamol 1 g (up to
a maximum dose of four times a day (QDS)) for pain
throughout the study period.
The following concomitant medications are prohibited
during the study period: opioid analgesia, capsaicin
cream/high-dose capsaicin patches, lidocaine patches,
anti-inflammatory medications (e.g. diclofenac, cole-
coxib), other antiepileptic medications (e.g. carbamaze-
pine), other antidepressant medications (e.g. SSRIs,
MAOIs), other neuropathic pain medications (e.g.
venlafaxine, intravenously administered (IV) lignocaine,
etc.), use of any medications that could lead to poten-
tially serious interactions with study medications.
Blood sample collection
Blood samples will be stored for future research which
may include genetic analysis. Samples will be obtained at
the same time as other study blood samples from parti-
cipants who have given additional (optional) consent.
The blood will be frozen and stored locally before being
shipped to a central laboratory.
Study procedures
The study assessment schedule (SPIRIT Figure; Fig. 3)
below details the assessments required during the course
of one treatment pathway. All participants will complete
three treatment pathways and this schedule will be re-
peated from week 0 to week 16 until all three pathways
are complete. Week 17 will only be relevant at the end
of the final pathway.
Primary outcome
The primary outcome is the difference between 7-day
average 24-h pain (evaluated at patient level) on an
11-point NRS scale (0 = no pain and 10 = worst pain im-
aginable) measured during the final follow-up week of
the treatment cycle (week 16) among pathways. The
NRS 24-h average pain is now considered the ‘gold
standard’ for the assessment of neuropathic pain and has
been employed in almost all well-designed neuropathic
pain studies over the past 10 years [15, 20, 21].
Fig. 1 Participant flow
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Secondary outcomes
Efficacy
1. Difference between 7-day average 24-h pain
(evaluated at patient level) on an 11-point NRS
scale at week 6 among monotherapies
2. Difference between RAND short form 36
(RAND SF-36) physical mean scores (evaluated
at patient level) at week 16 among pathways
[22]
3. Difference between RAND SF-36 physical mean
scores (evaluated at patient level) at week 6 among
pathways [22]
4. Difference between RAND SF-36 mental mean
scores (evaluated at patient level) at week 16 among
pathways [22]
5. Difference between RAND SF-36 mental mean
scores (evaluated at patient level) at week 6 among
pathways [22]
6. Difference between Hospital Anxiety and
Depression Scale (HADS) mean anxiety scores
(evaluated at patient level) at week 6 among
pathways [23].
7. Difference between Hospital Anxiety and Depression
Scale (HADS) mean anxiety scores (evaluated at
patient level) at week 16 among pathways [23]
First Treatment Phase Second Treatment Phase* 




1 1 4 1 1                      8 
Amitriptyline                                   Pregabalin 
A-P 
AM Placebo Placebo Placebo x 2 75mg 150mg 150mg x 2 
PM 25mg 50mg 25mg + 50mg 75mg 150mg 150mg x 2 
Duloxetine                                   Pregabalin 
D-P 
AM Placebo 30mg 30mg x 2 75mg 150mg 150mg x 2 
PM 30 mg 30mg 30mg x 2 75mg 150mg 150mg x 2 
Pregabalin                                 Amitriptyline 
P-A 
AM 75mg 150mg 150mg x 2 Placebo Placebo Placebo x 2 
PM 75mg 150mg 150mg x 2 25mg 50mg 25mg + 50mg 
First Treatment Phase Second Treatment Phase* 




1 1 4 1 1                      8 
Amitriptyline                                   Pregabalin 
A-P 
AM Placebo Placebo Placebo x 2 75mg 75mg 75mg  x 2 
PM 25mg 50mg 25mg + 50mg Placebo 75mg 75mg  x 2 
Duloxetine                                   Pregabalin 
D-P 
AM Placebo 30mg 30mg x 2 75mg 75mg  75mg  x 2 
PM 30 mg 30mg 30mg x 2 Placebo 75mg 75mg  x 2 
Pregabalin                                 Amitriptyline 
P-A 
AM 75mg 75mg 75mg  x 2 Placebo Placebo Placebo x 2 
PM Placebo 75mg 75mg  x 2 25mg 50mg 25mg + 50mg 
Fig. 2 a Dosing and titration schedule for each treatment pathway (standard pregabalin dosing, estimated glomerular filtration rate (eGFR)≥ 60 ml/
min). *Participants continue on the maintenance dose of drug from the first treatment phase for the duration of the second treatment phase. b
Dosing and titration schedule for each treatment pathway (reduced pregabalin dosing, eGFR 30–59 ml/min). *Participants continue on the
maintenance dose of drug from the first treatment phase for the duration of the second treatment phase
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8. Difference between Hospital Anxiety and
Depression Scale (HADS) mean depression scores
(evaluated at patient level) at week 6 among
pathways [23]
9. Difference between Hospital Anxiety and
Depression Scale (HADS) mean depression scores
(evaluated at patient level) at week 16 among
pathways [23]
10. Difference in proportion of patients having
treatment success (30%) at week 16 among
pathways. Treatment success is defined as a
reduction in 30% value of 7-day average NRS score
at follow-up compared to baseline
11. Difference in proportion of patients having
treatment success (50%) at week 16 among
pathways. Treatment success is defined as a
reduction in 50% value of 7-day average NRS score
at follow-up compared to baseline
Difference in Brief Pain Inventory – modified short
form (BPI-MSF) measure of pain interference with func-
tion total score (evaluated at patient level) at week 6
among pathways [24]
12. Difference in BPI-MSF measure of pain interference
with function total score (evaluated at patient level)
at week 16 among pathways [24]
13. Difference in Insomnia Severity Index (evaluated
at patient level) total score at week 6 among
pathways [25]
14. Difference in Insomnia Severity Index (evaluated at
patient level) total score at week 16 among
pathways [25]
15. Difference in Patient Global Impression of Change
(evaluated at patient level) at week 16 among
pathways [26]
16. Difference in proportion of care pathway preferred
by participants at week 50
Cost-effectiveness
17. EuroQoL-5D-5 L: the EQ-5D is a routinely used
generic HRQL instrument. It is the preferred instru-
ment for assessing HRQL by NICE, and the newer
five-level (EQ-5D-5 L) instrument offers increased
sensitivity as opposed to the original three-level
version [27]
Fig. 3 Study assessment schedule (Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure). aThis visit is only required
prior to randomisation, i.e. before starting the first treatment pathway. b Between scheduled study visits, the research nurse will contact the
participant by telephone each week (a minimum of once per week). The nurse will confirm compliance with medication and remind the
participant to complete study diaries/questionnaires. c Visits must normally be within ± 2 days of the scheduled visit date. Scheduled visit dates
relate to the date of the previous visit. Where this is impossible, e.g. due to bank holidays or patient availability. d Week-8 visit only required for
participants on combination treatment. e At the week-16 visit, participants will be given instructions to tape-off the current study treatment. Visits
from week 0 to week 16 will be repeated until all 3 pathways have been completed. f Week 17 is only applicable following the final pathway. g
FBC, urea and electrolytes, liver function tests, glycosylated haemoglobin A1c and serum creatinine. h hole blood sample to be collected and
stored for future research. The sample can be obtained at the same time as any scheduled blood test for the study. Please refer to the OPTION-
DM Sample Collection Manual for details. i Height (at week − 2 only), weight, heart rate and blood pressure (lying and standing). j To be
completed by participants daily during the study, starting during the washout period. Pain scores may also be collected via daily text messages
where participants have given additional consent for this. k Only required at week 0 of pathway 1, i.e. randomisation visit. l.Not required at week 0
of pathway 1, i.e. randomisation visit
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18. A modified version of the Client Service Receipt
Inventory (CSRI): the CSRI is a routinely used
instrument to capture health resource use and
personal expenses. Unnecessary questions will be
removed to reduce participant burden [28]
Safety
20. Frequency and proportion of patients reporting at
least one Adverse Event for each of the pathway.
Additionally, the relationship to intervention
(Definite, Probable, Possible, Unlikely, Unrelated,
Not assessable) will be reported (frequency and
proportion)
21. Frequency and proportion of Adverse Events for
each of the pathways
22. Listing of Adverse Events for each of the pathways
23. Frequency and proportion of patients reporting at
least one Serious Adverse Event for each of the
pathways. Additionally, these characteristics will be
summarised (frequency and proportion): intensity
(Mild, Moderate, Severe), relationship (Definite,
Probable, Possible, Unlikely, Unrelated, Not
assessable), is SUSAR, is Death
24. Frequencies of Serious Adverse Events for each of
the pathways
25. Listing of Serious Adverse Events for each of the
pathways
Subgroup
Neuropathic Pain Symptom Inventory (NPSI) question-
naire for subgroup analysis relating pain phenotype to
treatment response [29]. There is emerging evidence
that treatment response may be determined by a
patient’s pain phenotype [30–32]. In particular, these
outcomes will be evaluated:
26. Difference between ‘Burning (superficial)
spontaneous pain’ NPSI mean subscores –
(evaluated at patient level) at week 6 among
pathways
27. Difference between ‘Burning (superficial)
spontaneous pain’ NPSI mean subscores –
(evaluated at patient level) at week 16 among
pathways
28. Difference between ‘Pressing (deep) spontaneous
pain’ NPSI mean subscores – (evaluated at patient
level) at week 6 among pathways
29. Difference between ‘Pressing (deep) spontaneous
pain’ NPSI mean subscores – (evaluated at patient
level) at week 16 among pathways
30. Difference between ‘Paroxysmal pain’ NPSI mean
subscores – (evaluated at patient level) at week 6
among pathways
31. Difference between ‘Paroxysmal pain’ NPSI mean
subscores – (evaluated at patient level) at week 16
among pathways
32. Difference between ‘Evoked pain’ NPSI mean
subscores – (evaluated at patient level) at week 6
among pathways
33. Difference between ‘Evoked pain’ NPSI mean
subscores – (evaluated at patient level) at week 16
among pathways
34. Difference between ‘Paresthesia/dysaesthesia’ NPSI
mean subscores – (evaluated at patient level) at
week 6 among pathways
35. Difference between ‘Paresthesia/dysaesthesia’ NPSI
mean subscores – (evaluated at patient level) at
week 16 among pathways
36. Difference between NPSI mean total scores –
(evaluated at patient level) at week 6 among
pathways
37. Difference between NPSI mean total scores –
(evaluated at patient level) at week 16 among
pathways
Patient-perceived tolerability
38. Difference between tolerability (evaluated at patient
level) on an 11-point NRS scale at week 16 among
pathways-.
39. Difference between tolerability (evaluated at patient
level) on an 11-point NRS scale at week 6 among
monotherapies
Sample size
A 1-point change in an individual on the NRS scale is
considered a minimum clinically important difference
[33]. Hence, the proportion of patients improving by at
least 1 point would seem a suitable outcome. However,
we have based the sample size calculation on a continu-
ous outcome, the mean change between groups in order
to maintain power [34]. We have chosen a mean change
at the population level of 0.5 points between groups
based on the effect size previously reported for compari-
son of two active interventions for neuropathic pain in a
crossover study [35]. Based on Normal Distribution The-
ory we estimate that a 0.5-point shift in population
means will lead to an additional 8% of individual patients
achieving a 1-point improvement [36]. We have also
used a conservative, Bonferroni-corrected significance of
1.67% in order to retain an overall 5% false-positive
probability for finding a significant pairwise comparison.
Using a within-patient SD of 1.65 [35], an alpha of
0.0167 and 90% power, we require 294 evaluable patients
[37]. Assuming a 25% dropout rate 392 patients will be
randomised to ensure that 294 patients are expected to
complete the study.
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Withdrawals
An individual participant may stop treatment early for
any of the following reasons:
 Unacceptable toxicity
 Withdrawal of consent for treatment by the
participant
 Inter-current illness which prevents further
treatment
 Any alteration in the participant’s condition which
justifies the discontinuation of treatment in the
investigator’s opinion
 Pregnancy
Participants will be followed up as per the trial sche-
dule until the end of the current treatment pathway,
provided they are willing. A discussion will also take
place to clarify whether the participant is discontinuing
all study treatment or whether they wish to return for
the next treatment pathway.
When a participant stops treatment in the OPTION-
DM study, they will return to their usual care provider
for treatment outwith the study. At the end of the trial,
when the final analysis has been completed, the CTRU
will provide participating sites with the unblinded treat-
ment allocations for each of their participants. The site
staff will be responsible for contacting each of the partici-
pants to notify them of the treatment allocations. It will
then be a clinical decision between the participant and their
usual care provider as to which treatment they receive.
Data collection and management
Participant confidentiality will be respected at all times and
the principles of the UK Data Protection Act (DPA) will be
followed. The study will use the CTRU’s in-house data
management system (Prospect) for the capture and storage
of study-specific participant data. Access to Prospect is
controlled by usernames and encrypted passwords, and a
comprehensive privilege management feature will be used
to ensure that users have access to only the minimum
amount of data required to complete their tasks. A member
of staff at each site will enter data from source documents
into the study-specific Prospect database when available.
After data have been entered, electronic validation rules are
applied to the database on a regular basis; discrepancies are
tracked and resolved through the Prospect database. Ques-
tionnaires are self-completed by participants and entered
onto the study database by the research nurse. Data will be
stored and managed in accordance with CTRU Standard
Operating Procedures (SOPs).
Statistical analysis
The statistical analysis will be reported according to
Consolidated Standards of Reporting Trials (CONSORT)
guidelines [38] and using an intention-to-treat approach
as the primary analysis. As three pairwise comparisons
will be performed, all statistical tests will be two-tailed at
a 1.67% significance level. The primary outcome and
other continuous outcomes will be analysed using a
random-effects model with participant, treatment, se-
quence and period entered into the model. Participant
will be entered as a random term. Contrasts will be used
to evaluate the difference in means. Three 98.33% confi-
dence intervals for the difference on treatment effect will
be reported as well as the associated P value.
In case of missing data, the missing data mechanism
will be explored and multiple imputation may be applied
as a sensitivity analysis as appropriate. Other sensitivity
analyses will be performed in order to evaluate the
robustness of the primary analyses [39].
A logistic regression will be undertaken to analyse
binary outcomes using a model similar to that for the
continuous outcomes. Differences between treatment
groups will be reported as odds ratios with associated
98.33% confidence intervals and P values. Full details of
the statistical analyses will be specified in a detailed
Statistical Analysis Plan.
Monitoring
Conduct of this study will be governed by three commit-
tees. An independent Trial Steering Committee (TSC)
will oversee the conduct of the trial. An independent
Data Monitoring and Ethics Committee (DMEC) will
monitor participant safety. A Trial Management Group
(TMG) will be responsible for the day-to-day running of
the trial. The roles and responsibilities of the groups are
included in the group charter or terms of reference.
CTRU will undertake monitoring visits at each investi-
gator site before, during and after the trial. Central
monitoring will also be utilised to review data, consent
forms and accountability logs.
Details of Adverse Events will be collected at each
study visit or telephone call. Serious Adverse Events will
be assessed by the local investigator and reported to
Sheffield CTRU within 24 h.
Ethics and dissemination
Ethical approval for the study was given by Yorkshire
and the Humber – Sheffield Research Ethics Committee
(reference number: 16/YH/0459). Any protocol amend-
ments will be reviewed and approved by the Ethics
Committee and regulatory authority as applicable before
being notified to all relevant parties.
The results of the trial will be disseminated in
peer-reviewed scientific journals and clinical and aca-
demic conferences. A lay summary of the results will be
sent directly to participants. The results will also be
freely available via the funding body’s journal website
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[40] and a summary will be published on the Sheffield
CTRU website.
Patient public involvement
The Diabetes PPI Panel at Sheffield Teaching Hospitals
reviewed the study at the proposal development stage.
They were supportive of the proposal including the
study design and they contributed to the choice of end-
points for the study. In particular, they were pleased with
the efficient crossover design as participants will receive
active treatment during all treatment phases. Although
the duration of the study is long, they felt that partici-
pants are more likely to remain in the study as active
treatment is received. The panel were later involved in
the development of the patient information sheet,
consent form and study medication diary. We also have
a patient representative as a member of the TSC; there-
fore, we will have ongoing patient involvement in the
management of the study.
Discussion
DPNP is a distressing and disabling condition which is
often intractable to treatment. Unfortunately current
treatment only achieves meaningful pain relief in two
out of three patients. Despite much research there are
no current or emerging treatments that alter the natural
course of the disease. This study is timely as it addresses
an important clinical need by providing evidence as to
which is the most clinically beneficial and cost-effective
treatment pathway for DPNP.
Why examine treatment pathways?
The examination of a treatment pathway as a whole is
the most efficient and applicable to current UK clinical
practice. This is because most patients are started on
monotherapy and will require a second agent added in
combination within a few months [41]. Only a very small
minority will either have sufficient benefit from monother-
apy and will not need another agent, or will not tolerate
monotherapy (or monotherapy is completely ineffective)
and will be switched to another agent. Thus, OPTION-
DM, which will examine the whole treatment pathway, will
capture more clinically relevant outcomes than artificially
designed, head-to-head monotherapy or combination
studies. Hence, the outcomes of this study will be readily
generalisable to current UK clinical practice.
Why exclude gabapentin?
There is clear rationale for not studying two α-2-δ
agonists (pregabalin and gabapentin) as:
1. The evidence for gabapentin is only derived from
one reasonable-quality RCT (4-week titration and
4-week treatment phase) [42] compared to eight
RCTs in pregabalin and evidence supported by
meta-analysis [15]
2. Gabapentin is a thrice daily drug
3. Gabapentin, unlike pregabalin does not have linear
pharmacokinetics and requires a long titration
period of up to 2 months [43] to avoid toxicity
Which treatment pathways?
We will not examine the pathway of pregabalin supple-
mented by duloxetine because of the COMBO-DN find-
ings [44]. In this study, there was no difference in pain
reduction if pregabalin was added to duloxetine or vice
versa [44]. However, duloxetine was superior to pregaba-
lin as an initial treatment, is a once daily preparation
and is also the cheaper option in the UK. There is thus a
good rationale for starting patients on duloxetine and
then adding pregabalin in combination. Finally, as both
amitriptyline and duloxetine are antidepressants there is
little rationale for combining both.
Efficient design with 16-week treatment pathways
This will be an efficiently designed head-to-head,
crossover RCT [21] with each patient undergoing all
pathways. The duration of monotherapy in each path-
way is at least 6 weeks, an adequate duration to
assess treatment effect and whether combination the-
rapy is indicated [21, 43]. The subsequent 10-week
combination therapy in patients with partial benefit
from monotherapy will be adequate to assess stabi-
lised treatment outcomes [44]. The COMBO-DN
study used fixed-dose-titration regimens regardless of
treatment response. This resulted in a dropout rate of
17% during monotherapy and 12% during combi-
nation therapy [44]. The present trial is a pragmatic
RCT employing a flexible dosing regimen to achieve
maximum-tolerated doses based on individual responses;
we envision that this will reduce the dropout rate. The use
of rescue medication, frequent clinic and telephone
contacts and the need for active therapy we envision will
further reduce dropout rates. Completion rates will be
monitored on an ongoing basis.
Trial status
The current protocol is version 7.0, 1 February 2018.
The study began recruiting in November 2017 and is es-
timated to be completed in October 2018. Follow-up will
continue for a further 12 months. We anticipate that the
results will be available in early 2020.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist. (DOC 119 kb)
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